Complete remission of renal cell carcinoma with lung carcinomatous lymphangiosis after primary therapy with immune checkpoint inhibitors followed by partial nephrectomy for surgical consolidation

被引：0

作者：

Kambe, Takanari ^{[1
]}

Yamasaki, Toshinari ^{[1
]}

Mine, Yuta ^{[1
]}

Hagimoto, Hiroki ^{[1
]}

Kokubun, Hidetoshi ^{[1
]}

Kubota, Masashi ^{[2
]}

Tsutsumi, Naofumi ^{[1
]}

Inoue, Koji ^{[3
]}

Hara, Shigeo ^{[4
]}

Kawakita, Mutsushi ^{[1
]}

机构：

[1] Kobe City Med Ctr Gen Hosp, Dept Urol, Kobe, Hyogo, Japan

[2] Kyoto Univ Hosp, Dept Urol, Kyoto, Japan

[3] Kurashiki Cent Hosp, Dept Urol, Kurashiki, Okayama, Japan

[4] Kobe City Med Ctr Gen Hosp, Dept Pathol, Kobe, Hyogo, Japan

来源：

IJU CASE REPORTS | 2022年 / 5卷 / 03期

关键词：

carcinomatous lymphangiosis; cytoreductive nephrectomy; immune checkpoint inhibitor; metastatic renal cell carcinoma; robot-assisted partial nephrectomy; CYTOREDUCTIVE NEPHRECTOMY;

D O I：

10.1002/iju5.12427

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Introduction: Cytoreductive nephrectomy has been used in combination with systemic therapy for the treatment of metastatic renal cell carcinoma, although its efficacy in the era of immune checkpoint inhibitors remains controversial. Case presentation: A 57-year-old woman was diagnosed with left renal cell carcinoma and lung carcinomatous lymphangiosis (cT3aN0M1). After receiving combined immunotherapy, she achieved complete response for the lung metastases and partial response for the primary tumor. After fivemonths of systemic therapy, she underwent partial nephrectomy to remove the primary tumor, followed by eight courses of nivolumab monotherapy. One year postoperatively, she remained recurrence-free. Conclusion: Cytoreductive partial nephrectomy for surgical consolidation may be a treatment option for metastatic renal cell carcinoma.

引用

页码：168 / 171

页数：4

共 50 条

[31] Frailty Index in predicting surgical outcomes after partial nephrectomy in patients with renal cell carcinoma
Rosiello, G.
Re, C.
Cei, F.
Basile, G.
Musso, G.
Fallara, G.
Belladelli, F.
Cignoli, D.
Canibus, D.
Pinto, Soares S. P.
Necchi, A.
Marandino, L.
Karakiewicz, P. I.
Rowe, I.
Villa, G.
Boarin, M.
Disabato, N.
Trevisani, F.
Bettiga, A.
Briganti, A.
Montorsi, F.
Salonia, A.
Larcher, A.
Capitanio, U.
EUROPEAN UROLOGY, 2023, 83
[32] Complete Response in Metastatic Clear Cell Renal Cell Carcinoma Patients Treated with Immune-Checkpoint Inhibitors: Remission or Healing? How to Improve Patients' Outcomes?
Thouvenin, Jonathan
Masson, Claire
Boudier, Philippe
Maillet, Denis
Kuchler-Bopp, Sabine
Barthelemy, Philippe
Massfelder, Thierry
CANCERS, 2023, 15 (03)
[33] Combination therapy of immune checkpoint and nuclear exporter inhibitors in a renal cell carcinoma mouse model
Trott, Josephine
Anderson, Katie
Kim, Jeffrey
Graef, Ashley
Shacham, Sharon
Landesman, Yosef
Sarver, Aaron
Modiano, Jaime
Weiss, Robert H.
CANCER RESEARCH, 2016, 76
[34] CYTOREDUCTIVE NEPHRECTOMY IS ASSOCIATED WITH IMPROVED SURVIVAL FOR SARCOMATOID METASTATIC RENAL CELL CARCINOMA PATIENTS TREATED BEFORE OR AFTER SURGERY WITH IMMUNE CHECKPOINT INHIBITORS
Paz, Lotan
Jose, A. Karam
Viraj, A. Master
Philippe, E. Spiess
Charles, C. Peyton
Sarah, P. Psutka
Jay, D. Raman
Chiara, Mercinelli
Edouard, Nicalse
Nicholas, D. Robertson
Barry, Sirard R.
Amber, Jani
Manley, Wade J.
Brandon, Manley
Dattatraya, Patil
Glenn, O. Allen
Surena, F. Matin
Jason, Abel E.
Daniel, D. Shapiro
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2025, 43 (03)
[35] Re: Upfront Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors or Targeted Therapy: An Observational Study from the International Metastatic Renal Cell Carcinoma Database Consortium
Liu, Jianliang
Moon, Daniel
Lawrentschuk, Nathan
EUROPEAN UROLOGY, 2023, 84 (02) : 244 - 245
[36] Re: Geraldine Pignot, Antoine Thiery-Vuillemin, Jochen Walz, et al. Nephrectomy After Complete Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma: A New Surgical Challenge? Eur Urol 2020;77:761-3 The Next Surgical Frontier in Kidney Cancer: Nephrectomy After Immune Checkpoint Inhibition
Singla, Nirmish
Margulis, Vitaly
EUROPEAN UROLOGY, 2020, 78 (02) : E79 - E80
[37] Acute renal failure in patient with renal cell carcinoma after combination immune checkpoint inhibitor therapy
Zang, Peter D.
Lee, Ramon O.
Smith, Joshua A.
CURRENT PROBLEMS IN CANCER: CASE REPORTS, 2021, 4
[38] POSITIVE SURGICAL MARGINS AFTER PARTIAL NEPHRECTOMY FOR RENAL CELL CARCINOMA: PREDICTORS AND IMPACT ON ONCOLOGICAL OUTCOMES
Bansal, Rahul
Kapoor, Anil
Finelli, Antonio
Rendon, Ricardo
Moore, Ron
Breau, Rodney
Lacombe, Louis
Kawakami, Jun
Drachenberg, Darrel
Black, Peter
Pautler, Stephen
Liu, Zhihui
Tanguay, Simon
JOURNAL OF UROLOGY, 2014, 191 (04): : E545 - E545
[39] Impact of positive surgical margin after radical and partial nephrectomy for renal cell carcinoma: A multicenter analysis
Saitta, C.
Cerrato, C.
Capitanio, U.
Autorino, R.
Beatrici, E.
Pandolfo, S.
Meagher, M.
Antonelli, A.
Veccia, A.
Amparore, D.
Simone, G.
Tuderti, G.
Lughezzani, G.
Buffi, N.
Tanaka, H.
Pati, D.
Master, V.
Fujii, Y.
Porpiglia, F.
Montorsi, F.
Derweesh, I.
EUROPEAN UROLOGY, 2024, 85 : S2161 - S2162
[40] Positive surgical parenchymal margin after laparoscopic partial nephrectomy for renal cell carcinoma: Oncological outcomes
Permpongkosol, Sompol
Colombo, Jose R., Jr.
Gill, Inderbir S.
Kavoussi, Louis R.
JOURNAL OF UROLOGY, 2006, 176 (06): : 2401 - 2404

← 1 2 3 4 5 →